Levosalbutamol

證據等級: L5

預測適應症: 10 個

Levosalbutamol: From Asthma to Obstructive Lung Disease

One-Sentence Summary

Levosalbutamol is the pure (R)-enantiomer of salbutamol (albuterol), a selective β2-adrenoceptor agonist established internationally as a first-line bronchodilator for asthma and COPD, yet currently holding no formal market approval in India. The TxGNN model predicts it may be effective for Obstructive Lung Disease — the indication with the highest clinical evidence quality among all 10 predictions — supported by multiple Phase 3 RCTs (including a dedicated Levalbuterol-in-COPD trial) and 20 publications. Note: the highest TxGNN-score prediction is nasal cavity disease (score 99.99%, rank #1), but this carries only L4 evidence with a Hold recommendation; obstructive lung disease (score 99.85%, rank #10) is the only prediction among the ten that warrants an actionable recommendation.

Quick Overview

Item	Content
Original Indication	No India registration; established internationally for bronchial asthma and COPD
Predicted New Indication	Obstructive Lung Disease (Asthma / COPD)
TxGNN Prediction Score	99.85% (TxGNN rank #10 by score; evidence quality rank #1 among all 10 predictions)
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available for this record. Based on established pharmacology, Levosalbutamol (levalbuterol) is the (R)-enantiomer of salbutamol — a short-acting selective β2-adrenoceptor agonist (SABA). Upon binding to β2-adrenoceptors on airway smooth muscle cells, it activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), activates protein kinase A (PKA), and inhibits myosin light-chain kinase — the result is smooth muscle relaxation and prompt bronchodilation. This is the central pharmacological mechanism for acute bronchospasm reversal in both asthma and COPD.

The rationale for using the single-isomer formulation over racemic salbutamol/albuterol rests on two established observations. First, essentially all β2-agonist bronchodilatory activity resides in the (R)-enantiomer, meaning levosalbutamol delivers equivalent therapeutic effect at half the total drug load. Second, the (S)-enantiomer present in racemic formulations has been shown in in vitro and some human studies to carry pro-inflammatory and potentially bronchoconstricting properties — risks that are completely eliminated by the pure (R)-isomer formulation.

Obstructive lung disease — encompassing asthma exacerbations and COPD acute flares — is precisely the therapeutic domain where levosalbutamol’s mechanism is most directly applicable. Multiple head-to-head RCTs confirm its non-inferiority or superiority to racemic albuterol in clinical outcomes. The TxGNN prediction score of 99.85% aligns tightly with this mechanistic rationale. The principal barrier to India market access is regulatory, not scientific — no approved formulation currently exists in India despite a robust international evidence base.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00665600	Phase 3	Completed	257	Double-blind, multicenter, 6-week study of Levalbuterol (Levosalbutamol) specifically in COPD patients; direct evidence for this molecule in obstructive lung disease
NCT02170532	Phase 4	Completed	10	Directly compared aerosolised β-agonist isomers including Levosalbutamol (R-isomer) vs. racemic albuterol in asthma patients; measured lung function and enantiomer-specific effects via spirometry and impedance
NCT04446637	Phase 3	Withdrawn	0	Ipratropium/Levosalbutamol 20/50 mcg fixed-dose combination via pMDI vs. free combination in moderate-to-very-severe COPD — most directly relevant study design; withdrawn before enrollment began
NCT01012765	Phase 3	Completed	173	3-way crossover: indacaterol vs. placebo vs. tiotropium in moderate COPD; high-quality RCT establishing class-level evidence for bronchodilators in obstructive lung disease
NCT01274325	Phase 3	Completed	51	Salbutamol-containing ICS/LABA (Seroflo 125) vs. Seretide for airway inflammation in asthma; methodology directly applicable to levosalbutamol comparative study design
NCT00776984	Phase 3	Completed	453	48-week RCT of tiotropium as add-on in severe persistent asthma; high-quality parallel-group design establishing background evidence for bronchodilator combination therapy
NCT01096017	Phase 3	Completed	24	Head-to-head: terbutaline Turbuhaler vs. salbutamol pMDI in Japanese adult asthma patients; β2-agonist head-to-head methodology directly applicable to levosalbutamol vs. albuterol comparison
NCT00523991	Phase 4	Completed	457	24-week study of tiotropium + PRN albuterol vs. placebo + PRN albuterol in treatment-naïve COPD; confirms the essential role of rescue SABA in obstructive disease management
NCT02867761	Phase 3	Completed	780	RETHINC trial: long-acting bronchodilator in symptomatic smokers with normal spirometry; characterises the broader spectrum of obstructive disease responsive to bronchodilators
NCT02427165	Phase 2	Completed	29	7-way crossover of RPL554 vs. salbutamol (active comparator) vs. placebo via nebuliser in chronic asthma; salbutamol/levosalbutamol class used as gold-standard reference bronchodilator

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36594293	2023	RCT	Mymensingh Med J	Head-to-head RCT: Levosalbutamol vs. racemic salbutamol in acute asthma exacerbation; establishes L1 direct evidence for the drug in obstructive lung disease
22364295	2012	Treatment Evaluation	Expert Opin Pharmacother	Comprehensive treatment evaluation of Levosalbutamol specifically for COPD; covers pharmacology, clinical evidence, safety profile, and therapeutic positioning
21453221	2011	Review	Expert Opin Pharmacother	(R)-salbutamol in asthma and COPD: reviews enantiomer rationale, β2-agonist mechanism, and clinical data supporting levosalbutamol over racemic mixture
38803713	2024	Retrospective Cohort	Cureus	Retrospective cohort in hospitalised COPD patients: levalbuterol vs. albuterol impact on length of stay and direct medical costs in China
17276051	2007	RCT	Resp Medicine	Randomised double-blind crossover: bronchodilator response of levosalbutamol vs. salbutamol via pMDI in patients with obstructive airway disease
17337829	2007	Evidence Review	Indian J Pediatrics	Evidence-based review of levosalbutamol: pharmacology, comparative efficacy vs. racemic salbutamol, and clinical implications for obstructive airways disease
15293593	2004	Clinical Review	J Am Osteopathic Assoc	Clinical review of levalbuterol in asthma and COPD: dosing regimens, safety profile, and rationale for single-isomer use over racemic mixture
19671384	2009	Review	Curr Allergy Asthma Reports	Systematic comparison of levalbuterol vs. albuterol: enantiomer effects on airway inflammation, corticosteroid interaction, and clinical outcomes in obstructive disease
11236808	2001	PK Study	Clin Pharmacokinetics	Pharmacokinetics of levosalbutamol: enantioselective disposition, clinical implications for dosing optimisation, and rationale for the single-isomer development programme
17983880	2007	Guidelines	J Allergy Clin Immunol	EPR-3 Expert Panel Report: NAEPP guidelines for asthma diagnosis and management; contextualises SABA (including levalbuterol) as an essential component of all asthma treatment steps

India Market Information

Levosalbutamol currently has no registered products in India. The regulatory data shows 0 licenses and a market status of “Not Marketed.” Any clinical use in India would require either a special import authorisation or a formal New Drug Application (NDA) submission to CDSCO (Central Drugs Standard Control Organisation). Reference safety data from the originator’s package insert should be obtained to support such an application.

Safety Considerations

Drug Interactions (146 total interactions identified; key interactions listed below):

Interacting Drug	Level	Clinical Note
Isometheptene	Moderate	Additive sympathomimetic and cardiovascular effects
Epinephrine	Moderate	Additive adrenergic stimulation; increased cardiovascular risk
Clarithromycin	Moderate	Potential QT prolongation; ECG monitoring advised
Dolasetron	Moderate	Additive QT prolongation risk
Palonosetron	Moderate	Additive QT prolongation risk
Cisapride	Moderate	QT prolongation risk; avoid co-administration where possible
Famotidine	Moderate	QT-related interaction; cardiac monitoring advised
Ephedrine	Moderate	Additive adrenergic stimulation; increased tachycardia risk
Diethylpropion	Moderate	Additive sympathomimetic effects
Insulin (inhalation, rapid acting)	Moderate	Levosalbutamol may antagonise hypoglycaemic effect; monitor blood glucose

136 additional interactions are on record. A comprehensive DDI review is required before clinical use is initiated.

Please refer to the originator package insert for complete key warnings and contraindications (currently unavailable; flagged as a Blocking data gap).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Levosalbutamol has L1-grade evidence supporting its use in obstructive lung disease, anchored by a completed Phase 3 RCT of Levalbuterol specifically in COPD (NCT00665600, 257 patients), a direct head-to-head RCT versus racemic salbutamol in acute asthma (PMID 36594293), and a comprehensive literature base of 20 publications spanning pharmacokinetics, clinical efficacy, and pharmacoeconomics. The mechanistic rationale for the single-isomer formulation is well-established and scientifically sound, and the drug’s safety profile is consistent with the broader β2-agonist class.

To proceed, the following is needed:

Regulatory filing: Prepare and submit an NDA or bridging dossier to India’s CDSCO; no current domestic registration exists and this is the primary barrier to market entry
Full DDI review: Systematically evaluate all 146 identified drug interactions, with priority on QT-prolonging agents (clarithromycin, dolasetron, palonosetron, cisapride) and sympathomimetics (epinephrine, ephedrine)
Safety documentation: Obtain originator package insert to extract formal key warnings and contraindications (Blocking data gap DG001)
MOA documentation: Retrieve complete DrugBank mechanism of action data to support dossier preparation (High-severity data gap DG002)
Pharmacoeconomic modelling: Assess cost-benefit of branded levosalbutamol vs. widely available generic racemic albuterol in the Indian healthcare context, given the significant cost differential between single-isomer and racemic formulations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.